Nanostics
Clinical trials sponsored by Nanostics, explained in plain language.
-
Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies
Diagnosis OngoingThis study is testing whether a new blood test called ClarityDX Prostate can better identify men who have clinically significant prostate cancer. The test is given to men aged 40-75 with elevated PSA levels (3 ng/mL or higher) who are already scheduled for a prostate biopsy. Rese…
Sponsor: Nanostics • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
Smarter prostate screening: a new risk score aims to cut unnecessary biopsies
Diagnosis ENROLLING_BY_INVITATIONThis trial is testing whether a blood-based risk score called ClarityDX Prostate can help doctors decide which men truly need an MRI or biopsy when checking for prostate cancer. The test combines standard PSA levels with age and other factors to give a personalized risk estimate.…
Phase: NA • Sponsor: Nanostics • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC